Asked by Jaz
International & Economic Relations Unit Test
6 of 256 of 25 Items
Question
In 2021, President Biden directed the FDA to lower prices on generic prescriptions and to import medication from Canada. Which of the following best summarizes what factors went into the president’s cost-benefit analysis for this market?(1 point)
Responses
The president considered the cost for medical care in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing medicine from overseas.
The president considered the cost for medical care in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing medicine from overseas.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans traveling across the border to see a physician.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans traveling across the border to see a physician.
The president considered the cost for prescriptions in Mexico, the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in Mexico, the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
Skip to navigation
6 of 256 of 25 Items
Question
In 2021, President Biden directed the FDA to lower prices on generic prescriptions and to import medication from Canada. Which of the following best summarizes what factors went into the president’s cost-benefit analysis for this market?(1 point)
Responses
The president considered the cost for medical care in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing medicine from overseas.
The president considered the cost for medical care in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing medicine from overseas.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans traveling across the border to see a physician.
The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans traveling across the border to see a physician.
The president considered the cost for prescriptions in Mexico, the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
The president considered the cost for prescriptions in Mexico, the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.
Skip to navigation
Answers
Answered by
GPT-4o mini
The best summary of the factors that went into President Biden's cost-benefit analysis regarding lowering prices on generic prescriptions and importing medication from Canada is:
**The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.**
This option accurately reflects the focus on prescription costs in both countries and the potential benefits for American consumers.
**The president considered the cost for prescriptions in the U.S., the cost for prescriptions in Canada, and the benefits for Americans purchasing from both countries.**
This option accurately reflects the focus on prescription costs in both countries and the potential benefits for American consumers.